A 2-year phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis: Results from the 3-month double-blind period - 21/08/11
Stephen Tyring, MD, PhD, MBA, University of Texas Health Science Center, Houston, TX, United States; Leslie Rosoph, North Bay Dermatology Center, North Bay, ON, Canada; Darryl Toth, MD, Probity Medical Research, Windsor, ON, Canada; Ralph Zitnik, MD, Amgen, Inc., Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF. P2700 Dr. Tyring has performed research supported by Amgen, but has no Amgen stock or other financial interest in Amgen. Leslie Rosoph and Dr. Toth are principal investigators for Amgen. Dr. Zitnik is an Amgen employee. Writing support and poster production provided by Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by Wyeth Research |
Vol 52 - N° 3S
P. P171 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?